These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 29611519)

  • 1. Genetic testing for young women with breast cancer.
    Metcalfe K; Akbari MR; Narod SA
    Lancet Oncol; 2018 Apr; 19(4):e182. PubMed ID: 29611519
    [No Abstract]   [Full Text] [Related]  

  • 2. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
    Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
    JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of BRCA1/2 mutation testing among young survivors of breast cancer.
    Kehl KL; Shen C; Litton JK; Arun B; Giordano SH
    Breast Cancer Res Treat; 2016 Jan; 155(1):165-73. PubMed ID: 26706041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic testing in women with breast cancer: implications for treatment.
    Paterson R; Phillips KA
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life trajectories, genetic testing, and risk reduction decisions in 18-39 year old women at risk for hereditary breast and ovarian cancer.
    Hamilton R; Williams JK; Bowers BJ; Calzone K
    J Genet Couns; 2009 Apr; 18(2):147-59. PubMed ID: 18979190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory development from studies with young women with breast cancer who are BRCA mutation negative.
    Hamilton R; Kopin S
    ANS Adv Nurs Sci; 2013; 36(2):E41-53. PubMed ID: 23644270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
    J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.
    Mai PL; Lagos VI; Palomares MR; Weitzel JN
    Ann Surg Oncol; 2008 Dec; 15(12):3415-21. PubMed ID: 18836779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations.
    Lawrence WF; Peshkin BN; Liang W; Isaacs C; Lerman C; Mandelblatt JS
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):475-81. PubMed ID: 11352857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Decision Making and Genetic Testing for Breast Cancer: Mainstreaming Mutations.
    Katz SJ; Kurian AW; Morrow M
    JAMA; 2015 Sep; 314(10):997-8. PubMed ID: 26203642
    [No Abstract]   [Full Text] [Related]  

  • 13. Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan.
    Bando H
    Breast Cancer; 2014 Nov; 21(6):656-63. PubMed ID: 23754181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
    Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
    Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic test and prophylactic treatment in breast cancer families].
    Miyoshi Y; Noguchi S
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):512-22. PubMed ID: 11977534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies.
    Evans DG; Harkness E; Lalloo F; Howell A
    J Med Genet; 2014 Sep; 51(9):573-80. PubMed ID: 25053764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.
    Francken AB; Schouten PC; Bleiker EM; Linn SC; Rutgers EJ
    Breast; 2013 Oct; 22(5):561-8. PubMed ID: 23972475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.
    Grimmett C; Brooks C; Recio-Saucedo A; Armstrong A; Cutress RI; Gareth Evans D; Copson E; Turner L; Meiser B; Wakefield CE; Eccles D; Foster C
    Support Care Cancer; 2019 Jan; 27(1):297-309. PubMed ID: 29955974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative genetic testing affects surgical decision making in breast cancer patients.
    Lokich E; Stuckey A; Raker C; Wilbur JS; Laprise J; Gass J
    Gynecol Oncol; 2014 Aug; 134(2):326-30. PubMed ID: 24910453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic testing for young women with breast cancer - Authors' reply.
    Eccles DM; Copson ER
    Lancet Oncol; 2018 Apr; 19(4):e183. PubMed ID: 29611520
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.